Screener
ANI Pharmaceuticals ANIP Generics and Other — Selling, General and Administrative Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| (in thousands) | Generics and Other | Rare Disease and Brands | Corporate and Unallocated | Total |
|---|---|---|---|---|
| Net Revenues | $100,656 | $165,388 | — | $266,044 |
| Cost of sales (excluding depreciation and amortization) | 51,398 | 48,760 | — | 100,158 |
| Research and Development expense | 11,186 | 3,561 | — | 14,747 |
| Selling, general, and administrative expense | 1,578 | 60,719 | 29,364 | 91,661 |
| Depreciation and amortization | — | — | 19,640 | 19,640 |
| Contingent consideration fair value adjustment | — | — | (622) | (622) |
| Operating Income (Loss) | $36,494 | $52,348 | $(48,382) | $40,460 |
| Unrealized gain on investment in equity securities | — | — | $741 | $741 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's generics and other — selling, general and administrative expense?
- ANI Pharmaceuticals (ANIP) reported generics and other — selling, general and administrative expense of $1.58M in Q2 2026.
- How has ANI Pharmaceuticals's generics and other — selling, general and administrative expense changed year-over-year?
- ANI Pharmaceuticals's generics and other — selling, general and administrative expense increased by 13.6% year-over-year, from $1.39M to $1.58M.
- What is the long-term trend for ANI Pharmaceuticals's generics and other — selling, general and administrative expense?
- Over 3 years (2022 to 2025), ANI Pharmaceuticals's generics and other — selling, general and administrative expense has grown at a 12.7% compound annual growth rate (CAGR), from $3.96M to $5.68M.
- What does generics and other — selling, general and administrative expense mean?
- Encompasses the overhead costs related to the management, marketing, and administrative support functions dedicated to the generics business segment. It provides insight into the operational leverage and the cost structure required to support the segment's commercial activities.
Ask your AI about ANI Pharmaceuticals's generics and other — selling, general and administrative expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude